Study of the Anti-bacterial and Anti-tumor Effects of Calycosin
Archives of Advances in Biosciences,
Vol. 14 No. 1 (2023),
19 February 2023
,
Page 1-8
https://doi.org/10.22037/aab.v14i1.41056
Abstract
Introduction: The spread of antibiotic-resistant pathogenic strains has led to growing concerns in the world. One of the solutions to overcome this global problem is to research natural compounds and find natural ones with antibacterial properties. In this research, therefore, the antibacterial effects of calycosin on some important pathogens were studied. Also, we studied the antitumor effects of calycosin on HT-29 cell line.
Materials and Methods: After preparation of calycosin, its antioxidant capacity was measured. Then, the indicated strains were prepared from the microbiology department of Tehran Medical University and were then cultured. The disk diffusion, microdilution and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium (MTT) methods were used for evaluating antibacterial activity, determining minimum inhibition concentration (MIC), studying the antitumor effects of calycosin, respectively.
Results: Calycosin showed a strong antioxidant capacity and its IC50 for 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging was measured to be 120 μg/ml. The study of the antibacterial effects of calycosin indicated that it was more effective on gram-positive bacteria than gram-negative bacteria. The MIC of calycosin for pathogens E. coli, Shigella dysenteriae, Salmonella typhimurium, Staphylococcus aureus and Bacillus cereus was calculated to be 32, 32, 40, 26 and 28 µg/ml, respectively. To determine the synergistic effects, a concentration of 1.2 MIC of calycosin was used along with antibiotics; the results indicated the synergistic effects of antibiotics and calycosin on the studied pathogens, except for Staphylococcus aureus. Calycosin reduced HT-29 cell line viability at 2000µg/mL.
Conclusion: In general, it was concluded that calycosin has strong antibacterial activity on the pathogens used, especially Gram-positive bacteria Staphylococcus aureus and Bacillus cereus; besides, it has synergistic effects with antibiotics. In this field, in vivo and clinical studies are needed.
- Bacteria
- Calycosin
- Pathogen
- Synergism
How to Cite
References
Krishnaiah D, Sarbatly R, Nithyanandam R. A review of the antioxidant potential of medicinal plant species. Food Bioprod Process. 2011; 89(3):217-33. [DOI: 10.1016/j.fbp.2010.04.008]
Wang D, Hu G, Wang J, Yan D, Wang M, Yang L, et al. Studying CNS effects of Traditional Chinese Medicine using zebrafish models. J Ethnopharmacol. 2021; 267:113383. [DOI: 10.1016/j.jep.2020.113383] [PMID]
Yu D, Duan Y, Bao Y, Wei C, An L. Isoflavonoids from Astragalus mongholicus protect PC12 cells from toxicity induced by l-glutamate. J Ethnopharmacol. 2005; 98(1):89-94. [DOI: 10.1016/j.jep.2004.12.027] [PMID]
Or PMY, Lam FFY, Kwan YW, Cho CH, Lau CP, Yu H, et al. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms. Phytomedicine. 2012; 19(6):535-44. [DOI: 10.1016/j.phymed.2011.12.005] [PMID]
Zou J, Li W, Wang G, Fang S, Cai J, Wang T, et al. Hepatoprotective effects of Huangqi decoction (Astragali Radix and Glycyrrhizae Radix et Rhizoma) on cholestatic liver injury in mice: Involvement of alleviating intestinal microbiota dysbiosis. J Ethnopharmacol. 2021; 267:113544. [DOI: 10.1016/j.jep.2020.113544]
Hoo RLC, Wong JYL, Qiao CF, Xu A, Xu HX, Lam KSL. The effective fraction isolated from Radix Astragali alleviates glucose intolerance, insulin resistance and hypertriglyceridemia in db/db diabetic mice through its anti-inflammatory activity. Nutr Metab (Lond). 2010; 7(1):67. [DOI: 10.1186/1743-7075-7-67] [PMID]
Gong AGW, Duan R, Wang HY, Kong XP, Dong TTX, Tsim KWK, et al. Evaluation of the Pharmaceutical Properties and Value of Astragali Radix. Medicines. 2018; 5(2). [DOI: 10.3390/medicines5020046] [PMID]
Huang C, Li R, Shi W, Huang Z. Discovery of the anti-tumor mechanism of calycosin against colorectal cancer by using system pharmacology approach. Med Sci Monit. 2019; 25:5589. [DOI: 10.12659/MSM.918250] [PMID]
Guo C, Tong L, Xi M, Yang H, Dong H, Wen A. Neuroprotective effect of calycosin on cerebral ischemia and reperfusion injury in rats. J Ethnopharmacol. 2012; 144(3):768-74. [DOI: 10.1016/j.jep.2012.09.056] [PMID]
Ma C-H, Wang R-R, Tian R-R, Ye G, Fan M-S, Zheng Y-T, et al. Calycosin 7-O-β-D-glucopyranoside, an anti-HIV agent from the roots of Astragalus membranaceus var. mongholicus. Chem Nat Compd. 2009; 45(2):282-5. [DOI: 10.1007/s10600-009-9305-2]
Fan Y, Wu D-Z, Gong Y-Q, Zhou J-Y, Hu Z-B. Effects of calycosin on the impairment of barrier function induced by hypoxia in human umbilical vein endothelial cells. Eur J Pharmacol. 2003; 481(1):33-40. [DOI: 10.1016/j.ejphar.2003.09.007] [PMID]
Liu X, Sun X, Deng X, Lv X, Wang J. Calycosin enhances the bactericidal efficacy of polymyxin B by inhibiting MCR-1 in vitro. J Appl Microbiol. 2020; 129(3):532-40. [DOI: 10.1111/jam.14635] [PMID]
Griffin AS, West SA, Buckling A. Cooperation and competition in pathogenic bacteria. Nature. 2004; 430(7003):1024-7. [DOI: 10.1038/nature02744] [PMID]
Ogawara H. Comparison of Antibiotic Resistance Mechanisms in Antibiotic-Producing and Pathogenic Bacteria. Molecules. 2019; 24(19):3430. [DOI: 10.3390/molecules24193430] [PMID]
Wright GD. Antibiotic resistance in the environment: a link to the clinic?. Curr Opin Microbiol. 2010; 13(5):589-94. [DOI: 10.1016/j.mib.2010.08.005] [PMID]
Cunha BA. ANTIBIOTIC SIDE EFFECTS. Med Clin North Am. 2001; 85(1):149-85. [DOI: 10.1016/s0025-7125(05)70309-6] [PMID]
Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol. 2010; 74(2):106-33. [DOI: 10.1016/j.critrevonc.2010.01.010] [PMID]
Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer–a systematic overview. Acta oncol. 2007; 46(4):504-16. [DOI: 10.1080/02841860701348670] [PMID]
Rejhová A, Opattová A, Čumová A, Slíva D, Vodička P. Natural compounds and combination therapy in colorectal cancer treatment. Eur J Med Chem. 2018; 144:582-94. [DOI: 10.1016/j.ejmech.2017.12.039] [PMID]
Tan J, Qin X, Liu B, Mo H, Wu Z, Yuan Z. Integrative findings indicate anti-tumor biotargets and molecular mechanisms of calycosin against osteosarcoma. Biomed Pharmacother. 2020; 126:110096. [DOI: 10.1016/j.biopha.2020.110096] [PMID]
Chen J, Zhao X, Li X, Wu Y. Calycosin induces apoptosis by the regulation of ERβ/miR-17 signaling pathway in human colorectal cancer cells. Food Funct. 2015; 6(9):3091-7. [DOI: 10.1039/c5fo00374a] [PMID]
Chen J, Hou R, Zhang X, Ye Y, Wang Y, Tian J. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PloS one. 2014; 9(3):e91245. [DOI: 10.1371/journal.pone.0091245] [PMID]
Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008; 3(2):163-75. [DOI: 10.1038/nprot.2007.521] [PMID]
Wang F, Zhao S, Li F, Zhang B, Qu Y, Sun T, et al. Investigation of antioxidant interactions between Radix Astragali and Cimicifuga foetida and identification of synergistic antioxidant compounds. PLoS One. 2014; 9(1):e87221. [DOI: 10.1371/journal.pone.0087221] [PMID]
Toukam PD, Tagatsing MF, Tchokouaha Yamthe LR, Baishya G, Barua NC, Tchinda AT, et al. Novel saponin and benzofuran isoflavonoid with in vitro anti-inflammatory and free radical scavenging activities from the stem bark of Pterocarpus erinaceus (Poir). Phytochemistry Letters. 2018;28:69-75. [DOI: 10.1016/j.phytol.2018.09.006]
Sun H, Yin M, Qian W, Yin H. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Med Sci Monit. 2018; 24:6178-86. [DOI: 10.12659/MSM.910201] [PMID]
Mukne AP, Viswanathan V, Phadatare AG. Structure pre-requisites for isoflavones as effective antibacterial agents. Pharmacogn Rev. 2011; 5(9):13-8. [DOI: 10.4103/0973-7847.79095] [PMID]
Bedenić B, Cavrić G, Vranić-Ladavac M, Barišić N, Karčić N, Tot T, et al. COMPARISON OF TWO DIFFERENT METHODS FOR TIGECYCLINE SUSCEPTIBILITY TESTING IN ACINETOBACTER BAUMANNII. Acta Clin Croat. 2018; 57(4):618-23. [DOI: 10.20471/acc.2018.57.04.02] [PMID]
Gao J, Liu ZJ, Chen T, Zhao D. Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali. Pharm Biol. 2014; 52(9):1217-22. [DOI: 10.3109/13880209.2013.879188] [PMID]
Mahabusarakam W, Deachathai S, Phongpaichit S, Jansakul C, Taylor WC. A benzil and isoflavone derivatives from Derris scandens Benth. Phytochemistry. 2004; 65(8):1185-91. [DOI: 10.1016/j.phytochem.2004.03.006] [PMID]
Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine. 2008; 15(8):639-52. [DOI: 10.1016/j.phymed.2008.06.008] [PMID]
Nie X, Zhou Y, Li X, Xu J, Pan X, Yin R, et al. Calycosin down-regulates c-Met to suppress development of glioblastomas. J Biosci. 2019; 44(4):96. [PMID]
- Abstract Viewed: 164 times
- PDF Downloaded: 139 times